Charles River Laboratories International (CRL) Cost of Revenue (2009 - 2025)

Charles River Laboratories International's Cost of Revenue history runs 17 years deep, the most recent figure standing at -$820.3 million for Q4 2025.

• In Q4 2025, Cost of Revenue fell 2107.79% year-over-year to -$820.3 million; the TTM figure through Dec 2025 stood at -$427.9 million (down 150.28% YoY), while the FY2025 annual figure was $429.8 million, up 15.43% from the prior year.
• Cost of Revenue for Q4 2025 stood at -$820.3 million, down from $109.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $664.8 million in Q3 2023, with the low at -$1.6 billion in Q4 2023.
• The 5-year median for Cost of Revenue is $93.0 million (2021), against an average of -$39.1 million.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue surged 653.48% in 2023, then tumbled 2107.79% in 2025.
• Charles River Laboratories International's Cost of Revenue stood at -$1.0 billion in 2021, then decreased by 8.31% to -$1.1 billion in 2022, then slumped by 51.82% to -$1.6 billion in 2023, then soared by 102.48% to $40.9 million in 2024, then sank by 2107.79% to -$820.3 million in 2025.
• Business Quant data shows CRL's Cost of Revenue at -$820.3 million in Q4 2025, $109.9 million in Q3 2025, and $143.1 million in Q2 2025.